{"filings":[{"id":95452,"accession_number":"0001787306-26-000039","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis Q1 2026 revenue $105.4M (+65% YoY); net loss narrows to $11.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue of $105.4M from ZORYVE, up 65% YoY but down 17% sequentially due to Q1 seasonality.","Net loss of $11.3M ($0.09 per share) vs $25.1M loss in Q1 2025; positive operating cash flow of $2.2M.","FY 2026 revenue guidance maintained at $480M–$495M; cash and equivalents $224.3M at quarter end.","Submitted sNDA for ZORYVE cream 0.05% in atopic dermatitis for infants 3–24 months; initiated Phase 1 for ARQ-234.","Completed dermatology sales force expansion; hired head of Primary Care Franchise to target pediatric providers."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":105398000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108538,"accession_number":"0001787306-26-000017","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis Q4 2025 revenue $127.5M, first profitable quarter; 2026 guidance raised to $480-495M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net product revenue $127.5M (+84% YoY, +29% sequential); full year $372.1M (+123% YoY).","Q4 net income $17.4M ($0.14 diluted EPS) vs net loss of $10.8M in Q4 2024; positive operating cash flow of $26.2M.","Raised 2026 net product revenue guidance to $480-495M from $455-470M.","Positive Phase 2 data for ZORYVE cream 0.05% in infants (3-24 months) with atopic dermatitis; sNDA submission expected Q2 2026.","sNDA accepted for ZORYVE cream 0.3% in plaque psoriasis down to age 2; PDUFA June 29, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":376072000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124986,"accession_number":"0001787306-25-000147","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Arcutis appoints Amit Munshi to Board; founder Chaudhuri retires, retains consulting role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bhaskar Chaudhuri retired from Board and Compensation Committee chair on Dec 3, 2025; no disagreement.","Chaudhuri entered consulting agreement through June 30, 2027 with hourly rate; options continue to vest.","Amit Munshi appointed Class II director and Compensation Committee chair effective Dec 4, 2025.","Munshi received initial option for 16,502 shares; eligible for prorated annual equity of ~$300,000 and cash retainers of $50,000 (Board) + $15,000 (chair).","Munshi previously served as CEO of Arena Pharmaceuticals (acquired by Pfizer for $6.7B) and Orna Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124985,"accession_number":"0001787306-25-000142","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis Q3 2025 net product revenue $99.2M (+122% YoY); turns profitable; FY2026 guidance $455-470M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $99.2M (+122% YoY, +22% sequential); driven by ZORYVE cream and foam.","Net income $7.4M ($0.06 EPS) vs net loss $41.5M ($0.33 loss per share) in Q3 2024.","FDA approved ZORYVE cream 0.05% for atopic dermatitis in children 2-5; launch by end of October.","Initial FY2026 net product revenue guidance of $455-$470M; peak ZORYVE sales target $2.6-3.5B.","Phase 2 trials started for ZORYVE foam 0.3% in vitiligo and hidradenitis suppurativa."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":246569000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141678,"accession_number":"0001787306-25-000122","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis Q2 product revenue $81.5M (+164% YoY); ZORYVE foam approved for scalp/body psoriasis","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $81.5M vs $30.9M YoY, driven by ZORYVE portfolio demand across four approved indications.","Net loss narrowed to $15.9M ($0.13/sh) from $52.3M ($0.42/sh) YoY; cash $191.1M as of June 30.","ZORYVE foam 0.3% approved in May 2025 for scalp/body psoriasis; sales commenced in June.","PDUFA date Oct 13, 2025 for ZORYVE cream 0.05% in children 2–5 with atopic dermatitis.","IND submitted for ARQ-234 (CD200R agonist); halted ARQ-255 (alopecia areata) program."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":147350000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159576,"accession_number":"0001787306-25-000096","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Arcutis sets director cash retainers at $50k-$35k, annual equity value at $300k; all proposals at annual meeting pass","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash retainers: $50k for non-employee directors; additional $35k for non-exec chair; committee chairs $20k (audit), $15k (comp), $10k (nominating).","Equity: initial option up to $300k value for new directors; annual award ~$300k split 65% option (up to $195k) and 35% RSU (up to $105k).","Plan amended effective June 11, 2025; board approved revisions to attract and retain qualified directors.","Shareholders reelected directors Chaudhuri, Lin, Welgus; ratified Ernst & Young as auditor; approved non-binding say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159575,"accession_number":"0001787306-25-000091","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis Q1 product revenue $63.8M (+196% YoY); net loss narrows; appoints new CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $63.8M, up 196% YoY; down 2% QoQ due to deductible resets.","Net loss $25.1M ($0.20/shr) vs $35.4M ($0.32/shr) YoY improvement.","Latha Vairavan appointed CFO effective May 6, 2025.","Patent litigation against Padagis stayed; all deadlines cancelled; 30-month extension.","PDUFA May 22 for ZORYVE foam 0.3% for scalp/body psoriasis; sNDA for cream 0.05% with PDUFA Oct 13."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":65846000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159574,"accession_number":"0001787306-25-000058","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Arcutis appoints Latha Vairavan as CFO; David Topper to retire effective May 15, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Latha Vairavan appointed SVP and CFO effective prior to Q1 10-Q filing; David Topper to retire with transition support through May 15, 2025.","Vairavan's base salary increased to $450,000, target annual bonus 45% of salary (max 67.5%), pro-rated for 2025.","Vairavan granted option to purchase 60,000 shares and 20,000 restricted stock units with standard vesting.","Topper's retirement not due to any dispute; he will receive severance benefits per existing agreement subject to release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177948,"accession_number":"0001787306-25-000028","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis Q4 ZORYVE revenue $69.4M (+413% YoY); net loss narrows to $10.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $71.4M vs $13.5M YoY; net loss $0.09/share vs $0.72/share prior year.","Full-year ZORYVE net product revenue $166.5M (+471% YoY); ZORYVE is #1 branded non-steroidal topical in U.S.","Submitted sNDA for ZORYVE cream 0.05% for atopic dermatitis in children ages 2-5; target action Q4 2025.","Prepaid $100M of $200M term loan; maintains ability to re-draw; cash & securities $228.6M at year-end.","ZORYVE foam for scalp/body psoriasis PDUFA date May 22, 2025; partnered with Odell Beckham Jr. for seborrheic dermatitis awareness."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":196542000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177947,"accession_number":"0001787306-25-000004","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis reports Q4 product revenue ~$63M (+366% YoY); FY2024 ~$160M (+449% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2024 product revenue ~$63M, up ~366% vs Q4 2023 and ~41% vs Q3 2024.","Full-year 2024 product revenue ~$160M, up ~449% compared to 2023, driven by ZORYVE demand.","Cash and marketable securities ~$229M as of Dec 31, 2024; total liquidity ~$329M after $100M debt repayment and re-draw option.","Gross-to-net similar to prior quarter; robust unit growth across portfolio.","Company to report complete Q4/FY2024 results and host conference call on Feb 25, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":196542000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194655,"accession_number":"0001787306-24-000151","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis Q3 revenue $44.8M (+452% YoY); net loss narrows to $41.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ZORYVE franchise revenue $44.8M ($22.0M cream 0.3%, $20.3M foam 0.3%, $2.5M cream 0.15%), up 45% QoQ.","Net loss $41.5M ($0.33/sh) vs $44.8M ($0.73/sh) in Q3 '23; operating cash burn improved 23% QoQ to $34.7M.","Blended gross-to-net improved to low 50% range from high 50% last quarter; approaching steady state for foam.","Amended $200M SLR loan: lower rate, maturity extended to Aug '29; prepaid $100M on Oct 8, 2024.","sNDA for ZORYVE foam in scalp/body psoriasis accepted; PDUFA May 22, 2025. Health Canada approval for foam in SD received."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":125182000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210958,"accession_number":"0001787306-24-000122","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis Q2 product revenue $30.9M, up 547% YoY; net loss narrows to $52.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ZORYVE franchise net product revenue $30.9M ($17.3M cream, $13.6M foam); 43% sequential growth.","Net loss $52.3M ($0.42/share) vs $71.0M loss in Q2 2023; cash $363.1M.","Entered co-promotion with Kowa Pharmaceuticals for primary care and pediatric promotion of ZORYVE.","Submitted sNDA for ZORYVE foam for scalp/body psoriasis; FDA approved cream 0.15% for atopic dermatitis.","Amended $200M term loan: rate reduced 150bps, maturity extended to June 2029, $100M prepay/re-draw option."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":80427000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229424,"accession_number":"0001787306-24-000090","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Arcutis stockholders elect three directors, ratify EY, approve say-on-pay at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All three Class I director nominees elected: Terrie Curran (77.2M for), Halley Gilbert (75.8M for), Keith R. Leonard Jr. (59.3M for).","Ratification of Ernst & Young as auditor for FY2024 passed with 95,949,963 votes for, 6,661 against.","Non-binding advisory vote on named executive officer compensation approved: 56,906,215 for, 26,716,602 against.","Meeting held June 14, 2024; record date April 22, 2024 with 115,524,989 shares outstanding and entitled to vote.","Broker non-votes of 12,428,038 on director election and say-on-pay proposals, none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229423,"accession_number":"0001787306-24-000078","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcutis Q1 product revenue $21.6M up 675% YoY; net loss narrows to $35.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 product revenue $21.6M ($15M cream, $6.5M foam) vs $2.8M in Q1 2023; 59% QoQ growth.","Net loss $35.4M ($0.32/sh) vs $80.1M ($1.31/sh) in Q1 2023; cash $404.5M at March 31.","PDUFA date July 7, 2024 for roflumilast cream 0.15% in atopic dermatitis (ages 6+).","Completed $172.5M public offering in February; licensing deal with Sato Pharma for Japan.","Appointed David Topper CFO effective April 10, 2024; sNDA for scalp/body psoriasis expected Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":49569000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229422,"accession_number":"0001787306-24-000046","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Arcutis appoints David Topper as CFO, replacing interim CFO John Smither","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Topper named CFO effective April 10, 2024; John Smither steps down and resigns April 30.","Topper receives $515k base salary, 45% target bonus, and equity awards of 310k options, 110k RSUs, 60k PSUs.","Topper brings 40+ years experience; most recently CFO at Inmagene, ex-General Atlantic, J.P. Morgan, Morgan Stanley.","Smither served as interim CFO since August 2023; previously Arcutis' first CFO leading IPO.","Topper's severance agreement includes 12 months base plus bonus, COBRA, and full equity acceleration on qualifying termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247981,"accession_number":"0001628280-24-008496","cik":1787306,"company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Arcutis raises ~$161.6M in public offering of 18.2M shares at $9.50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued ~18.2M shares at $9.50 via underwritten public offering, raising ~$161.6M net.","Underwriters fully exercised 30-day option to purchase additional 2,368,421 shares on Feb 29, 2024.","Net proceeds intended to fund commercialization, development, and approval for atopic dermatitis, scalp psoriasis, and psoriasis expansion.","Offering conducted under existing Form S-3 shelf registration (File No. 333-276794)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2723065003.499291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}